Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy

BACKGROUND: Based on data from two multicenter, phase III clinical trials (Studies 301 and 305), eribulin (a microtubule dynamics inhibitor) is indicated in the European Union (EU) for patients with locally advanced or metastatic breast cancer (MBC) after ≥1 prior chemotherapy for advanced disease,...

Descripción completa

Detalles Bibliográficos
Autores principales: Pivot, X., Marmé, F., Koenigsberg, R., Guo, M., Berrak, E., Wolfer, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4959925/
https://www.ncbi.nlm.nih.gov/pubmed/27177860
http://dx.doi.org/10.1093/annonc/mdw203

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4959925/
https://www.ncbi.nlm.nih.gov/pubmed/27177860
http://dx.doi.org/10.1093/annonc/mdw203

Ejemplares similares